FDA approves Enspryng as first subcutaneous at-home treatment for thyroid eye disease

The US FDA approved Roche/Genentech's Enspryng (satralizumab-mwge) as the first at-home subcutaneous treatment for thyroid eye disease (TED) in adults, marking the drug's second indication after neuromyelitis optica spectrum disorder (NMOSD). This approval follows mixed Phase III trial results and provides an alternative to infusion-based therapies.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.